Acquired Resistance to KRASG12C Inhibition in Cancer
Background Clinical trials of the KRAS inhibitors adagrasib and sotorasib have shown
promising activity in cancers harboring KRAS glycine-to-cysteine amino acid substitutions at …
promising activity in cancers harboring KRAS glycine-to-cysteine amino acid substitutions at …
Acquired Resistance to KRASG12C Inhibition in Cancer
MM Awad, S Liu, II Rybkin… - The New England …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Clinical trials of the KRAS inhibitors adagrasib and sotorasib have shown
promising activity in cancers harboring KRAS glycine-to-cysteine amino acid substitutions at …
promising activity in cancers harboring KRAS glycine-to-cysteine amino acid substitutions at …
[PDF][PDF] Acquired Resistance to KRAS (G12C) Inhibition in Cancer
MM Awad, S Liu, II Rybkin, KC Arbour, J Dilly - scholarlycommons.henryford.com
BACKGROUND Clinical trials of the KRAS inhibitors adagrasib and sotorasib have shown
promising activity in cancers harboring KRAS glycine-to-cysteine amino acid substitutions at …
promising activity in cancers harboring KRAS glycine-to-cysteine amino acid substitutions at …
[HTML][HTML] Acquired Resistance to KRASG12C Inhibition in Cancer
MM Awad, S Liu, II Rybkin, KC Arbour… - The New England …, 2021 - ncbi.nlm.nih.gov
BACKGROUND Clinical trials of the KRAS inhibitors adagrasib and sotorasib have shown
promising activity in cancers harboring KRAS glycine-to-cysteine amino acid substitutions at …
promising activity in cancers harboring KRAS glycine-to-cysteine amino acid substitutions at …
Acquired Resistance to KRASG12C Inhibition in Cancer
MM Awad, S Liu, II Rybkin, KC Arbour, J Dilly… - New England Journal …, 2021 - cir.nii.ac.jp
Acquired Resistance to KRAS<sup>G12C</sup> Inhibition in Cancer | CiNii Research CiNii 国立
情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす …
情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす …
Acquired Resistance to KRASG12C Inhibition in Cancer.
MM Awad, S Liu, II Rybkin, KC Arbour… - The New England …, 2021 - europepmc.org
Background Clinical trials of the KRAS inhibitors adagrasib and sotorasib have shown
promising activity in cancers harboring KRAS glycine-to-cysteine amino acid substitutions at …
promising activity in cancers harboring KRAS glycine-to-cysteine amino acid substitutions at …
Acquired Resistance to KRAS (G12C) Inhibition in Cancer
MM Awad, S Liu, II Rybkin… - The New …, 2021 - scholarlycommons.henryford.com
BACKGROUND: Clinical trials of the KRAS inhibitors adagrasib and sotorasib have shown
promising activity in cancers harboring KRAS glycine-to-cysteine amino acid substitutions at …
promising activity in cancers harboring KRAS glycine-to-cysteine amino acid substitutions at …